腹腔镜

Search documents
援圭亚那医疗队开展“中国医疗队手术日”活动
Xin Hua Wang· 2025-07-04 08:50
医疗队医生钱益(左一)、韩云(左二)与当地医生拉姆哈里(右一)在手术中(中国医疗队供图) 手术日当日,医疗队队长杜伯祥带领队员钱益、韩云组成手术团队前往西德梅拉拉医院为当地患者完成 了腹腔镜胆囊切除术、腹腔镜疝修补术各一例。手术过程中,外科医生钱益详细向助手拉姆哈里讲解每 一步手术的技术要领。此次腹腔镜疝修补手术在该院属于首次开展,这也吸引了外科的很多医生前来观 摩和学习。麻醉医生杜伯祥在精准调控麻醉过程的同时,也向当地同行示范了视频喉镜气管插管下的全 身麻醉新技术。中国医疗队手术团队以精湛的技术和高效的团队协作精神赢得了当地医护人员的高度评 价和肯定。 新华网加拉加斯7月4日电(记者田睿)乔治敦消息:第20期中国援圭亚那医疗队近日前往位于圭亚那行 政3区西德梅拉拉医院开展"中国医疗队手术日"活动。该项活动是中国援圭亚那医疗队在圭亚那卫生部 的倡导下到圭亚那基层医院开展的巡诊系列活动,旨在推动圭亚那基层医疗单位的医疗技术水平。 队长杜伯祥表示,上周我们在西德梅拉拉医院举办了"中国医疗队手术日"系列巡诊活动的启动仪式,同 时捐赠了一批医疗物资并促成了该活动的顺利开展。"手术日"活动旨在通过集中技术示范与临床带教 ...
康基医疗20250703
2025-07-03 15:28
康基医疗 20250703 摘要 全球微创外科耗材市场规模庞大,2024 年约为 320 亿美元,但年复合 增速仅为 5%,主要受欧美老龄化及欠发达地区开胸手术影响。中国市 场增速显著,预计未来五年复合增速达 12%,2024 年市场规模预计为 260 亿元,2028 年将达 407 亿元。 微创外科手术量在中国持续增长,预计从 2023 年的 1,400 万台增至 2028 年的 2,400 万台,耗材单价略有提升。集采政策导致穿刺器等产 品价格大幅下降,外资企业因成本压力退出,为康基等国产企业提供了 巨大的替代空间。 康基医疗的市场份额显著提升,从 2019 年的 2%-3%增长至 2023 年 的 14%左右,受益于国产替代加速。国际巨头如美敦力因成本问题退出 部分产线,其原副总裁也转投康基,进一步增强了康基的竞争力。 康基医疗在一次性穿刺器、高分子结扎夹、电凝钳等领域占据领先地位, 并积极拓展超声刀、吻合器和缝线等产品线。同时,康基也在腹腔机器 人领域进行布局,其子公司正在开发相关产品。 Q&A 康基作为中国微创耗材的龙头企业,在手术机器人领域的发展前景如何? 康基发布了其第一款腹腔镜手术机器人,预计 ...
我国医疗器械市场迈入万亿元规模 上市公司竞相加码布局
Zheng Quan Ri Bao· 2025-07-01 09:46
Core Insights - The Chinese medical device industry is projected to reach a market size of 1.2 trillion yuan by 2024, with logistics warehouse space totaling 23.58 million square meters and over 40,000 vehicles for medical logistics transportation [1] - The government is enhancing policy support for the medical device industry, focusing on expediting clinical trials and approvals for innovative medical devices [2][3] - Companies are actively expanding their market presence and capabilities in response to policy incentives and growing market demand [4][5] Industry Growth and Policy Support - The State Council has issued opinions to reform drug and medical device regulation, aiming to shorten clinical trial and registration timelines, particularly for high-end devices like medical robots and brain-computer interfaces [2] - Local governments, such as Zhejiang and Shanxi, are implementing measures to support innovation in medical devices, including expedited approval processes and enhanced healthcare coverage for innovative products [2][3] Company Strategies and Market Expansion - Companies like Di'an Diagnostics are leveraging AI and data to enhance their product offerings, with their AI pathology model achieving clinical-grade standards [4] - Kangji Medical's surgical robot has been approved for market release, marking a significant step in domestic production capabilities and reducing reliance on imports [4] - Yingte Group is investing in a modern pharmaceutical supply chain park to improve logistics capabilities, indicating a trend towards digital and intelligent solutions in the medical supply chain [5] - The medical device sector is becoming a key area for diversified growth among listed companies, driven by aging populations and supportive policies [5]
海泰新光(688677):海外库存消化拐点已至,未雨绸缪化解关税风险
China Post Securities· 2025-06-27 09:40
证券研究报告:医药生物 | 公司深度报告 发布时间:2025-06-27 股票投资评级 资料来源:聚源,中邮证券研究所 公司基本情况 | 最新收盘价(元) | 38.50 | | --- | --- | | 总股本/流通股本(亿股)1.20 | / 1.20 | | 总市值/流通市值(亿元)46 | / 46 | | 52 周内最高/最低价 | 43.47 / 25.73 | | 资产负债率(%) | 10.6% | | 市盈率 | 34.38 | | 第一大股东 | 青岛普奥达企业管理服 | | 务有限公司 | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 研究助理:陈峻 SAC 登记编号:S1340123110013 Email:chenjun@cnpsec.com 海泰新光(688677) 海外库存消化拐点已至,未雨绸缪化解关税风险 l 公司致力于探索光学技术与医学、工业及激光、生物识 别等多领域的融合创新 海泰新光主要从事医用内窥镜器械和光学产品的研发、生产和销 售。公司致力于探索光学技术与医学、工业及激光、生物识别 ...
【宝鸡】援藏医疗队为雪域高原群众健康保驾护航
Shan Xi Ri Bao· 2025-06-25 00:28
"我连自己的手都看不见,有时候会撞到墙上,或者打翻东西。"贡布一边说,一边用手指在空中无 意识地摸索,"听说,县里来了一支千里之外的医疗队,队员是来自陕西的医疗专家。家人赶紧带我过 来看病。" 宝鸡市人民医院眼科医院日间手术中心副主任、援藏医疗队成员张建峰带领医疗队与当地眼科团队 一起为贡布进行详细检查。"贡布视力仅存微弱光感,晶状体核硬度达到5级,加上高原低氧环境的影 响,手术难度很大。"张建峰说。 西藏自治区阿里地区医疗资源匮乏、医疗条件落后,群众就医不便。前不久,宝鸡援藏医疗队前往 西藏自治区阿里地区改则县进行医疗对口帮扶。 78岁牧民贡布被白内障困扰了3年,生活需要他人帮助。 "我们采用了翼状胬肉切除联合角膜缘干细胞移植术。该技术不仅能彻底清除病变组织,还能利用 患者自身干细胞促进角膜修复,降低复发风险。"张建峰说。 术后,旦增的视力提升至0.5,能够清晰辨认家人面容,甚至能独立阅读。"现在,我又能看清孙子 的笑容了。"旦增激动地说。 6月6日,在改则县第二小学的大礼堂,宝鸡援藏医疗队为200余名师生带来一场题为《防控近视增 强体魄 健康成长报效祖国》的近视防控科普讲座。 "这里紫外线强、空气干燥,眼 ...
多学科转化治疗+微创手术“双剑合璧” 为晚期肿瘤患者带来长期生存希望
Mei Ri Shang Bao· 2025-06-20 22:26
卢毅浙江省人民医院肝胆胰外科副主任医师 商报记者曾润玥通讯员杨陶玉马梦迪 随后卢毅团队为患者实施了腹腔镜胰十二指肠切除术,凭借着每年超百例的微创技术积累,卢毅成功将 手术时间从最初的8小时缩短至4.5个小时,并且患者术后第二天即可下床,10天顺利出院。如今五年过 去,王女士复查显示持续无瘤生存,"原本以为生命只剩半年时间,现在却能每天接送孙女上学,是转 化化疗给了我第二次生命。" 数据显示,转化化疗通过术前缩小原发肿瘤、消灭远处转移,可使部分晚期胰腺癌患者获得手术切除的 根治机会,5年生存率较传统治疗显著提高。 从"一刀切"到"量体裁衣" 转化治疗重构晚期肿瘤患者治疗新模式 无独有偶,67岁的李阿姨(化名)2年前因腹部胀痛就诊时,被确诊为胆囊癌伴肝脏及后腹膜淋巴结转 移,彻底失去了手术根治机会。"传统单纯化疗对晚期胆囊癌效果有限,患者平均生存不足半年。"为 此,卢毅团队创新采用了化疗联合PD-1抑制剂的转化治疗方案,4个周期化疗后影像学检查显示:后腹 膜淋巴结基本消失,肝脏转移灶缩小超60%,成功为机器人辅助微创胆囊癌根治术创造了条件。 "患者胆囊结石病史长达10年,结石长期对胆囊进行摩擦和刺激是癌变主因。" ...
烟威首例,毓璜顶医院成功完成充气纵隔镜联合腹腔镜食管癌根治术
Qi Lu Wan Bao Wang· 2025-06-20 08:29
传统手术不耐受,那就另辟蹊径 今年58岁的李先生,因吞咽困难而到烟台毓璜顶医院就诊,在完善各项检查明确诊断为胸下段食管癌后,各项检查未发现明确远处转 移,经医院MDT团队的会诊,建议首选治疗方法为手术治疗。 齐鲁晚报.齐鲁壹点孙淑玉通讯员李成修李凌峰 患者李先生4月下旬在烟台毓璜顶医院进行胃镜检查时,被发现患有"食管癌伴狭窄",并伴吞咽困难。由于他肺功能不佳,不能耐受传统 的胸腔镜手术,烟台毓璜顶医院胸外科副主任医师黄海波团队另辟蹊径,于近日成功为其进行了充气纵隔镜联合腹腔镜食管癌根治术。 该术式在降低患者心肺并发症概率的同时,还可以加快术后康复速度,填补了该术式在烟威地区的空白。 黄海波(右一)团队讨论患者病情 虽然以往也有不开胸的食管钝性拔脱手术,但手术不是在直视下进行,并发症较多,而且不能清扫纵隔内淋巴结,达不到肿瘤治疗的根 治性要求。黄海波说,"充气纵隔镜是通过颈部小切口,纵隔内充气建立操作空间,在纵隔内进行食管的游离及淋巴结的清扫,同时结合 腹腔镜完成腹部操作,实现肿瘤切除的全程微创化,而且能够达到肿瘤根治的目的。" 说起该手术的优势,黄海波告诉记者,"这种术式能基本保留胸膜腔的完整性,对于心肺功能 ...
海泰新光收盘下跌2.09%,滚动市盈率32.02倍,总市值45.98亿元
Sou Hu Cai Jing· 2025-06-19 13:15
青岛海泰新光科技股份有限公司的主营业务是医用内窥镜器械和光学产品的研发、制造、销售和服务。 公司的主要产品是4K荧光/白光腹腔镜、内窥镜光源模组、摄像适配器/适配镜头等。 最新一期业绩显示,2025年一季报,公司实现营业收入1.47亿元,同比24.86%;净利润4668.87万元, 同比21.45%,销售毛利率64.98%。 6月19日,海泰新光今日收盘38.36元,下跌2.09%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到32.02倍,总市值45.98亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均48.08倍,行业中值36.05倍,海泰新光排 名第70位。 截至2025年一季报,共有26家机构持仓海泰新光,其中基金22家、其他3家、社保1家,合计持股数 5706.80万股,持股市值21.45亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海泰新光32.0233.983.4245.98亿行业平均 48.0846.364.47103.51亿行业中值36.0536.602.3547.96亿1英科医疗9.5810.330.85151.42亿2九安医疗 10.061 ...
智通决策参考︱中东冲突又起,市场惯性会往黄金及油价方向走
智通财经网· 2025-06-16 01:23
Group 1: Market Overview - The ongoing conflict between Iran and Israel is causing market volatility, with the Hang Seng Index recently closing with a bearish candlestick pattern [2] - The market is closely monitoring the potential for escalation in the Iran-Israel conflict, with expectations that large-scale conflict is unlikely due to diplomatic efforts from the US and Russia [2][6] - The upcoming Federal Reserve interest rate decision on June 19 is anticipated to be influenced by rising oil prices, which have dampened expectations for a rate cut [2] Group 2: Oil and Shipping Industry - The intensity of the Iran-Israel conflict could significantly impact oil shipping rates, particularly if Iranian oil exports are disrupted, potentially removing 1.8 million barrels per day from the market [6] - The shipping sector is expected to be influenced by the geopolitical situation, with a focus on how the conflict may affect oil and gas negotiations and the potential for US intervention [6][7] - The sentiment surrounding the Iran-Israel conflict is expected to catalyze movements in shipping stocks, particularly those involved in oil transportation [8] Group 3: Investment Opportunities - The company MicroPort Scientific Corporation (02252) is projected to benefit significantly from the growing laparoscopic surgical robot market, with a forecasted compound annual growth rate of 43% from 2025 to 2030 [4] - The laparoscopic surgical robot market in China is expected to reach 11.2 billion RMB by 2030, with a compound annual growth rate of 21% over the next five years [5] - The company is positioned to capitalize on its cost advantages and comparable functionality to leading systems, which may enhance its market share in both domestic and international markets [5]
第十七批中国援厄立特里亚医疗队助力受援医院腹腔镜技术破百例
人民网-国际频道 原创稿· 2025-06-03 02:30
Core Viewpoint - The successful completion of the 100th laparoscopic surgery in Eritrea marks a significant milestone in the country's medical history, showcasing the achievements of the 17th Chinese medical team and the advancement of medical cooperation between China and Eritrea [1][4][8]. Group 1: Medical Achievements - The Chinese medical team initiated laparoscopic surgery in Eritrea, which was previously non-existent, and achieved a milestone of 100 successful surgeries within a year [1][2]. - The first laparoscopic surgery was performed on August 12, 2024, benefiting a 42-year-old appendicitis patient, demonstrating the efficiency of laparoscopic techniques compared to traditional open surgery [4][5]. - The medical team implemented a "1+1+1" teaching model, allowing local doctors to gain hands-on experience and eventually leading to one local doctor being able to perform surgeries independently [5][7]. Group 2: Training and Capacity Building - The team adopted a "three-step" strategy to establish laparoscopic surgery, which included hardware upgrades, technical training, and clinical practice [2]. - Local doctors received comprehensive training through theoretical lectures, simulated training, and on-site guidance, resulting in improved surgical skills and knowledge [2][5]. - The establishment of a minimally invasive center is planned to extend the training and techniques to surrounding provinces within three years [5][7]. Group 3: Cultural Exchange and Community Impact - The successful surgeries fostered a strong bond between the Chinese medical team and the local community, with expressions of gratitude from patients and local doctors [7][8]. - Celebratory events were held to honor the achievements, highlighting the cultural exchange and appreciation for the Chinese medical team's contributions [4][7]. - Over 80% of patients expressed positive feelings post-surgery, indicating a significant impact on patient satisfaction and community health perception [7].